Santen Pharmaceutical Co., Ltd.
Santen Pharmaceutical Co., Ltd. (SNPHY) Revenue
Annual & quarterly revenue history · segment & region breakdown
SNPHY · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsSanten Pharmaceutical Co., Ltd. trailing twelve-month (TTM) revenue is $296B, an increase of 3.07% year-over-year from $309B in FY2026.
Revenue trend
2026 – 2007 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2026-03-31 | $309B | +$9.21B | +3.07% |
| 2025-03-31 | $300B | -$1.96B | -0.65% |
| 2024-03-31 | $302B | +$22.93B | +8.22% |
| 2023-03-31 | $279B | +$12.78B | +4.80% |
| 2022-03-31 | $266B | +$16.65B | +6.67% |
| 2021-03-31 | $250B | +$8.05B | +3.33% |
| 2020-03-31 | $242B | +$7.53B | +3.22% |
| 2019-03-31 | $234B | +$9.08B | +4.04% |
| 2018-03-31 | $225B | +$25.85B | +12.98% |
| 2017-03-31 | $199B | +$3.81B | +1.95% |
Compare revenue vs peers
Drug Manufacturers - GeneralCompare SNPHY revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Santen Pharmaceutical Co., Ltd. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Santen Pharmaceutical Co., Ltd. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in JPY.
Data sourced from Santen Pharmaceutical Co., Ltd.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
SNPHY revenue · 4 questionsSNPHY's trailing twelve-month (TTM) revenue is $296B. That is an increase of 3.07% year-over-year from $309B in FY2026.
▸ Source: FMP · Santen Pharmaceutical Co., Ltd. SEC filings · GAAP · Santen Pharmaceutical Co., Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026